The Subject Expert Committee (SEC) on Oncology and Hematology, functioning under the Central Drugs Standard Control ...

Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline. Learn ...

Our findings highlight the molecular diversity and diagnostic challenges of HER2-mutated NSCLC in underrepresented ...

At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial ...

Trastuzumab deruxtecan with pertuzumab significantly extended progression-free survival in HER2-positive advanced breast cancer, compared to standard THP therapy, according to DESTINY-Breast09 trial ...

As practicing oncologists, we can get bogged down in our individual practices and thus have trouble seeing the bigger picture ...

There were no cases of HER2 positivity among patients with gliomas, sarcomas, small cell lung cancer, gastrointestinal stromal tumors, thyroid carcinoma, uterine sarcoma, thymic carcinoma, and Merkel ...

The National Agency for Food and Drug Administration and Control (NAFDAC) has raised a public health alert over the circulation ...

Biocon Biologics collaborates with Malaysia's National Cancer Society to launch a Patient Assistance Program, providing affordable biosimilars like Trastuzumab to underserved cancer patients and ...

Vital chemotherapy drugs used around the world have failed quality tests, putting cancer patients in more than 100 countries ...

A suit cannot be maintained under the Civil law, merely based on an apprehension of litigation, without any concrete or ...

Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.